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Abstract
The incidence of type 2 diabetes has proliferated and is associated with many problems,
including chronic kidney disease. The purpose of this quality improvement project was to
implement two evidence-based guidelines that may detect chronic kidney disease and slow
its progression in patients with type 2 diabetes by implementing angiotensin-converting
enzyme inhibitor or angiotensin receptor blocker therapy according to evidence-based
guidelines from the American Diabetes Association. Patients with type diabetes were
screened for microalbuminuria and eGFR of < 60 mL/min/1.73 m2. Based on lab results, the
provider recommended either an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker to patients with as appropriate. The primary aim of this project was to
achieve 80% implementation of an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker for patients with type 2 diabetes who met criteria. Second, seventy to 90
percent of early progression to chronic kidney disease among those with type 2 diabetes was
to be identified via blood and urine testing. One hundred and sixty-three patients with type 2
diabetes were seen during the implementation phase and screened, and one hundred and
thirty-two patients who needed an angiotensin-converting enzyme inhibitor or angiotensin
receptor blocker were placed on one or the other. Thirteen patients were on an angiotensinconverting enzyme inhibitor or an angiotensin receptor blocker prior to project
implementation. Introducing an angiotensin- converting enzyme inhibitor or angiotensin
receptor blocker as recommended for many patients with type 2 diabetes may slow the
progression of chronic kidney disease and improve quality of life.
Keywords: type 2 diabetes, chronic kidney disease, diabetic nephropathy, ACE inhibitor,
ARB, microalbuminuria, eGFR
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This paper describes a quality improvement project developed, implemented, and
evaluated by this Doctor of Nursing Practice (DNP) student in response to a deficit in meeting
diabetes guidelines from the American Diabetes Association (ADA, 2018) at a clinic serving a
low-income population. Type 2 diabetes (T2D) is one of the most serious chronic diseases in the
world in terms of its incidence, prevalence, economic and social impacts, and adverse effects on
quality of life (Da Silva et al., 2018). The incidence and prevalence of T2D have increased
exponentially in the United States and globally in past decades (Lai, 2016). According to the
Centers for Disease Control and Prevention (CDC, 2017a), 30.3 million Americans have
diabetes: 29.05 million have type 2 diabetes, and 1.25 million have type 1 diabetes. Among
Americans with diabetes, 23 million cases have been diagnosed, and 7.2 million people remain
undiagnosed (CDC, 2017a). Additionally, 84.1 million people in the United States have
prediabetes, which may lead to T2D within 5 years if not treated (CDC, 2017a). Additionally,
diabetes is the seventh leading cause of death among all persons in the United States and the fifth
leading cause of death among Hispanics (CDC, 2018).
Statement of the Problem
The DNP student reviewed care of patients with T2D at a primary care clinic serving a
low-income population. When reviewing medical records of patients with T2D, the student noted
that not all ADA evidence-based guidelines related to diabetes management were being
followed. Specifically, individuals diagnosed with T2D were not consistently receiving a urine
albumin test and were not being placed on an angiotensin-converting enzyme (ACE) inhibitor or
angiotensin-receptor blocker (ARB) as recommended by the ADA (2018).
Background and Significance
Type 2 diabetes is associated with many complications, and diabetic nephropathy and
chronic kidney disease (CKD) are among the most devastating complications with respect to

IMPLEMENTATION OF ACE INHIBITOR REGIMEN

10

patient survival and quality of life (Lai, 2016). Diabetic nephropathy is a syndrome characterized
by the presence of pathological quantities of urine albumin excretion, diabetic glomerular
lesions, and loss of glomerular filtration (Lim, 2014). Hyperglycemia associated with T2D is a
fundamental cause of vascular complications which may lead to diabetic nephropathy and CKD.
Poor glycemic control has also been associated with albuminuria (Lim, 2014). As the population
with T2D increases, diabetic nephropathy has become the leading cause of CKD (CDC, 2017b).
Approximately 1 in 3 adults with T2D may have CKD (CDC, 2017b). Adults with T2D, high
blood pressure, or both have a higher risk of developing CKD than those without these
conditions (CDC, 2017b). Other risk factors for CKD include heart disease, obesity, and a family
history of CKD (CDC, 2017b).
Diabetic nephropathy involves an increase in proteinuria and a reduction in glomerular
filtration rate (eGFR), which often results in kidney damage (Feng-Yi, Fang-Ju, Shih-Hui, &
Wang, 2017). Ongoing kidney damage can lead to irreversible renal failure, known as end-stage
renal disease (ESRD), which may eventually require dialysis or a kidney transplant (Feng-Yi et
al., 2017). Chronic kidney disease among persons with T2D can be detected during a routine
periodic health assessment, which should include urine testing for albumin and the albumin-tocreatinine ratio (ACR) and blood tests to assess eGFR (ADA, 2018). The glomerular filtration
rate is determined by serum creatinine levels, age, gender, and race and reflects how well the
kidneys are functioning. A urine check and ACR test detects the presence of the protein albumin,
which establishes preliminary progression of kidney damage (ADA, 2018). A single eGFR value
or albuminuria result is insufficient for a diagnosis of CKD. Therefore, these tests must be
repeated to confirm a diagnosis that identifies continuous progression of the defining
abnormality over a 3-month period (Romagnani et al., 2017).
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Diabetic nephropathy may be present at CKD onset and can progress to ESRD (ADA,
2018). Additionally, CKD markedly increases cardiovascular risk. The 2018 Standards of
Medical Care in Diabetes supports prescribing an ACE inhibitor or ARB to normotensive, nonpregnant persons with T2D who have microalbuminuria and an eGFR of <60 mL/min/1.73 m2 to
slow the progression of CKD (ADA, 2018). An ACE inhibitor or ARB therapy is not
recommended for primary prevention of diabetic nephropathy in patients with diabetes who have
normal blood pressure, normal creatinine (<30 mg/g Cr), and normal eGFR (ADA, 2018). When
the eGFR is <60 mL/min/1.73 m2, evaluation and management of potential complications of
CKD are required, and patients with an eGFR <30 mL/min/1.73 m2 should be referred to a
nephrologist for evaluation for renal replacement treatment (ADA, 2018).
According to the National Kidney Foundation (NKF, 2018), CKD has five stages as
listed in Table 1. In the first stage of kidney damage, patients present with normal kidney
function with an eGFR of > 90 mL/min/1.73m2. As kidney function deteriorates, patients with
Stage 2 CKD present with a reduction in eGFR ranging between 89 and 60 mL/min/1.73m2. In
Stage 3a, the eGFR ranges from 59 to 45 mL/min/1.73m2 with mild to moderate loss of function;
Stage 3b reflects moderate to severe loss of function with eGFR rates fluctuating from 40 to 30
mL/min/1.73m2. Stage 4 represents severe loss of kidney function, where the eGFR is between
29 to less than 15 mL/min/1.73m2. Stage 5 indicates kidney failure, also known as ESRD, with
an eGFR of < 15 mL/min/1.73m2 (NKF, 2018).
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Table 1
Stages of Chronic Kidney Disease Based on eGFR
GFR

% of kidney
function
90 or higher 90–100%

Stage 1

Kidney damage with normal kidney function

Stage 2

Kidney damage with mild loss of kidney function 89 to 60

89–60%

Stage 3a Mild to moderate loss of kidney function

59 to 45

59–45%

Stage 3b Moderate to severe loss of kidney function

44 to 30

44–30%

Stage 4

Severe loss of kidney function

29 to 15

29–15%

Stage 5

Kidney failure and need for dialysis or transplant < 15

< 15%

Note. Adapted from “Estimated Glomerular Filtration Rate” by National Kidney Foundation
(2018).
End-stage renal disease is the fifth and last stage of CKD and requires dialysis or kidney
transplantation as life-saving measures (NKF, 2018). Common symptoms include a lowered
ability or inability to urinate, confusion, fatigue, malaise, headache, loss of appetite, and dry skin
and itching (NKF, 2018). New cases of ESRD in the United States have indicated that 44% of
patients also have diabetes, 29% have high blood pressure, 20% of cases can be attributed to
some other cause, and 7% of cases occur due to unknown etiology (CDC, 2017b). Table 2
depicts the stages of CKD and the corresponding focus of kidney-related care; Table 3 presents
the classification of diabetic nephropathy by albuminuria level.
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Table 2
CKD Stages and Corresponding Focus of Kidney-related Care
CKD stage
Stage

Focus of kidney-related care
Evidence ofDiagnose
eGFR
(ml/min/1.73 kidney
cause of
m2 )
damage
kidney
injury

No clinical
evidence ≥ 60
of CKD

Evaluate and Evaluate and
treat risk
treat CKD
factors for
complications
CKD
progression

Prepare for
renal
replacement
therapy

-



1
≥90
+


2
60–89
+



3
30–59
+/


4
15–29
+/


5
<15
+/Note. Adapted from “Standards of Medical Care in Diabetes-2018,” by American Diabetes
Association, 2018, Diabetes Care, 41 p. s107.
Table 3
Classification of Diabetic Nephropathy by Albuminuria Level
Urine specimen

Microalbuminuria

Macroalbuminuria

Timed overnight collection

20–199 μg/min

≥200 μg/min

24-hour collection

30–299 mg/day

≥300 mg/day

Albumin concentration

20–300 mg/L

>300 mg/L

Albumin–creatinine ratio
(ACR)

Men: 2.5–30 mg/mmol

>30 mg/mmol

Women: 3.5–30 mg/mmol

>30 mg/mmol

Note. Adapted from “Diabetic Nephropathy: Diagnosis, Screening, and Management,” by R.
Bilous, 2013, Diabetes and Primary Care, 15, p. 90.
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Diabetic nephropathy is the most common cause of CKD worldwide; between 20% and
40% of patients with diabetes develop diabetic nephropathy (Prakash, 2015). Diabetic
nephropathy usually worsens over time and increased urinary protein excretion is the initial
clinical indicator. Persons who exhibit this complication are at increased risk of cardiovascular
disease and, if left untreated, diabetic nephropathy may lead to a rapid decline in renal function,
which may result in renal failure and the need for a kidney transplant (Sudhakar, Pasula, &
Simpson, 2014). Certain treatments have been shown to slow progression of CKD. Angiotensin
converting enzyme inhibitors or ARBs can make a significant difference for patients with
diabetes by reducing the risk of progression to CKD in normotensive patients with
microalbuminuria (ADA, 2018; Lai, 2016).
The use of an ACE inhibitor or ARB is recommended for non-pregnant individuals with
T2D who have a modestly elevated urinary albumin-to-creatinine ratio between 30 and 299 mg/g
creatinine. This intervention is strongly endorsed for those with a urine albumin-to-creatinine
ratio of 300 mg/g and/or an eGFR of 60 mL/min/1.73 m2 (ADA, 2018). Additionally, an
assessment of urinary albumin-to-creatinine ratio and eGFR should be performed for all patients
with T2D at least once per year (ADA, 2018). Monitoring a patient’s glucose level by checking
the hemoglobin A1c every three months and recommending appropriate treatment may further
reduce the risk or slow the progression of diabetic nephropathy (ADA, 2018). See Table 4 for a
list of recommended ACE/ARB medications and comments related to ordering these
medications.
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Table 4
Angiotensin-converting Enzyme (ACE) Inhibitors and Angiotensin II Receptor Blockers
Drug Class

Agent of Choice

Comments

ACE Inhibitor

Benazepril, Captopril, Enalapril,
Fosinopril, Lisinopril, Moexipril
Perindopril, Quinapril Ramipril,
Trandolapril

Do not use in combination with
ARBs or direct renin inhibitor
Increased risk of hyperkalemia,
especially in patients with CKD or
in those on K+ supplements or K+sparing drugs
May cause acute renal failure in
patients with severe bilateral renal
artery stenosis
Do not use if history of
angioedema with ACE inhibitors
Avoid in pregnancy

ARB

Azilsartan, Candesartan Eprosartan, Do not use in combination with
Irbesartan Losartan, Olmesartan
ACE inhibitors or direct renin
Telmisartan, Valsartan
inhibitor
Increased risk of hyperkalemia in
CKD or in those on K+
supplements or K+- sparing drugs
May cause acute renal failure in
patients with severe bilateral renal
artery stenosis
Do not use if history of
angioedema with ARBs
Patients with a history of
angioedema with an ACE inhibitor
can receive an ARB starting 6
weeks after ACE inhibitor
discontinued
Avoid in pregnancy

Note. Adapted from “Hypertension,” by J. Saseen and E. Maclaughlin, 2017, Pharmacotherapy:
A Pathophysiologic Approach, pp. 57–58.

IMPLEMENTATION OF ACE INHIBITOR REGIMEN

16

Studies have shown that ACE inhibitors and ARBs help slow the progression of CKD in
patients with T2D (Corbo, Delellis, Hill, Rindfuss, & Nashelsky, 2016; Qin et al., 2014;
Sudhakar et al., 2014). One meta-analysis included evidence of the effect of ACE/ARB
administration on mortality in patients with non-dialysis-dependent CKD (Qin et al., 2014).
Findings indicated that among 81,959 patients with this diagnosis, a protective effect was found
when ACEs or ARBs were used; this effect was associated with a reduced risk of all-cause
mortality compared with ACE or ARB non-use (Qin et al., 2014). Sudhakar et al. (2014)
demonstrated the value of reducing microalbuminuria related to diabetic nephropathy by
implementing ACE or ARB therapy in a double-blind controlled trial of 100 patients with T2D.
Findings revealed a reduction in 24-hour urine microalbuminuria after 3 months of treatment
with ACE or ARB therapy (Sudhakar et al., 2014). Another meta-analysis of randomized
controlled trials with disease-oriented outcomes reported that ACE inhibitors and ARBs reduced
the risk of progression to CKD in normotensive patients with microalbuminuria and T2D (Corbo
et al., 2016).
A systematic review of randomized controlled trials with a T2D population was
undertaken to review studies examining normoalbuminuric persons to assess the efficacy of
using ACE inhibitors or ARBs to slow the progression of CKD by comparing these interventions
to a placebo (Persson, Lindhardt, Rossing, & Parving, 2016). Only studies with 50 or more
participants in each arm were included for review. Ultimately, six trials encompassing 16,921
normoalbuminuric patients with T2D were included. After one year of follow-up evaluation of
the effect on the development of micro- or macroalbuminuria, results indicated a 16% relative
risk reduction for development of microalbuminuria in the ACE/ARB treatment group compared
to the placebo groups (Persson et al., 2016).
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Assessment
This project was conducted at a small, independently owned family practice clinic with
two sites, Clinic A and Clinic B. The clinic sites are in an urban area of the southwestern United
States, and both provide care to underserved populations. However, patients at the Clinic B tend
to be above poverty level. No appointment is needed at either site. The clinics are headed and
owned by a seasoned Doctor of Osteopathic Medicine with experience in emergency medicine
and family medicine. The clinics are open Monday through Friday from 9:00 a.m. to 6:00 p.m.
and 9:00 a.m. to 2:30 p.m. on Saturdays. Medicare is not accepted at the clinic, but private
insurance, Medicaid, and cash are accepted. The mission of this clinic is to provide quality health
services and improve the health of every patient who visits through a commitment to excellence.
The staff’s goal is to provide convenient, cost-effective care to the people they serve.
The clinic staff consists of one medical doctor, three nurse practitioners (NPs), eight
medical assistants (MAs), and two secretaries. All clinic staff are bilingual except for the owner.
The clinic manager works under the direction of the owner and is in charge of MAs and staff
scheduling. The clinic manager and owner communicate verbally or via e-mail to manage
changes in day-to-day operations.
The first clinic, Clinic A, is a 3000-square-foot facility with a waiting area, main desk
with a medical record room, six triage rooms, two procedure rooms, one physician room, one
manager’s office, and one laboratory. This clinic is on a bus line route that serves a densely
populated, low-income area with high rates of homelessness and recreational drug seeking. The
second clinic site, Clinic B, is 1500 square feet and has five triage rooms, two physician offices,
one laboratory, a manager’s office, and a waiting area for patients. Clinic B is in a blended lowincome and low-middle-class neighborhood with some homeless individuals in the area. It is also
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on a bus line route.
Clinic A sees approximately 10 to 20 patients per day, 30 to 80 per week, and 200 to 245
per month; Clinic B sees between 15 to 35 patients each day, 45 to 100 per week, and 250 to 345
per month. The total number of new patients seen at both clinics ranges from 75 to 130 per
month. Both clinic sites provide preventive medicine, primary care, and management of chronic
diseases. Some of the medical conditions treated include hypertension; diabetes; urinary tract
infections; and ear, nose, and throat problems. Other medical ailments such as asthma, sexually
transmitted infections, cough, sore throat, bronchitis, allergic rhinitis, hyperlipidemia,
gastrointestinal problems, pancreatitis, anemia, arthritis, back pain, and chest pain are common
diagnoses at both clinics. Minor surgical procedures such as stitches for lacerations, incisions
and abscess drainage, and ingrown toenail extraction are performed at the clinics.
Patients who visit the clinics range from 1 to 72 years old and older. Sixty-five percent of
the patients who visited the clinic sites at the time of this project were Hispanic/Latino, 10%
were Caucasian, 7% were Black or African American, 15% were Asian, and 3% were of another
race. Among patients who were Hispanic/Latino, most spoke more Spanish than English.
Patients’ educational backgrounds ranged from no formal education to a high school diploma or
college degree.
As part of the needs survey, the DNP student conducted an oral survey regarding patient
satisfaction. For patients who spoke Spanish only, the MAs served as interpreters while the
student asked questions. Fifty T2D patients were surveyed in English or Spanish over a twomonth period prior to identification of the project purpose and plan. Patients with T2D were
asked to indicate their responses on a 5-point Likert-type scale, with 1 being the worst and 5
being excellent. Questions regarding patient satisfaction included the amount of time patients
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waited to get an appointment, convenience of the office location, length of time waiting at the
office, time spent with the provider, provider’s explanation of what was done, provider’s
sensitivity to patient’s special needs or concerns, patient’s satisfaction with getting the help
needed, and feelings about overall quality of the visit. No identifying information (e.g., patient
name, record number, or date of birth) was collected during this survey.
Most of the clients indicated dissatisfaction in some areas of care as evidenced by their
scores and commentary. Questions with the lowest scores concerned time spent with the
provider, explanation of what was done, and the provider’s sensitivity to the patient’s special
needs or concerns. The mean scores on these three questions ranged between 2.48 and 2.7; see
Table 5 for complete results of the patient satisfaction survey.
Table 5
Patient Satisfaction Survey Results
Questions
Time it takes to receive
appointment
Convenience of clinic
location
Time waited before
seeing the provider
Time spent with provider 6

1=
Worst

Provider explanation of
10
disease and solution
Provider sensitivity to5
patients’ special needs or
concern
Satisfaction with care
10
received
Overall quality of visit
Note. N = 50 patients with T2D.

2=
Fair

3=
Good
1216

= Very Good
13

5=
Excellent
9

3.38

30

15

5

3.5

1520

10

5

3.1

2410

10

2.48

2015

5

2.3

1520

10

2.7

3010
2515

M

2
10

2.7
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The DNP student was granted access by the physician to review the medical history of
patients with T2D. With the assistance of the clinic manager, the number of patients seen at least
once between October 1, 2017 and September 30, 2018 was determined to be 947. Out of these,
255 (27%) had a pre-existing diagnosis of T2D. The aforementioned figures were determined
using the electronic medical record.
Next, 60 records of patients with a T2D diagnosis were chosen randomly and reviewed
by the DNP student for demographic information including each patient’s age, sex,
race/ethnicity, and education level. Information about patients’ past medical history, medication
history, allergy history, and the most recent results of urine screening (ACR) and eGFR, if
completed, were collected for baseline reference. The number of T2D patients with and without
medical insurance was noted. Twenty-five percent of the 60 reviewed records had a completed
ACR while approximately 60% of records had an eGFR lab result on record. Based on the DNP
student’s random evaluation of these records, only 25% of patients were on an ACE inhibitor or
ARB.
The DNP student provided the physician and NPs with electronic copies of the Standards
of Medical Care in Diabetes Guidelines-2018. The DNP student then met with providers and the
manager simultaneously to discuss a proposal for a quality improvement project. Based on
findings from the patient record review, the DNP student suggested a provider-level practice
change to order urine albumin and eGFR screening on all patients with T2D and to add an ACE
inhibitor/ARB as indicated by ADA evidence-based guidelines (2018). The DNP student
explained that implementation of this initiative could improve or slow the progression of CKD.
Specifically, the student discussed that the ADA (2018) standards recommended that an ACE
inhibitor or ARB be prescribed to non-pregnant individuals with T2D who exhibited “modestly
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elevated urinary albumin-to-creatinine ratio between 30–299 mg/g creatinine and strongly
recommended [it] for those with a urine albumin-to-creatinine ratio of 300 mg/g creatinine
and/or eGFR of 60 mL/min/1.73 m2” (ADA, 2018, p. S105). The physician and NPs recognized
the need for a change in practice and were willing to implement the project.
The DNP student met with the clinic manager and the MAs on a subsequent day with the
physician’s permission. During that meeting, the DNP student explained the initiative and
clarified that the project was not intended to blame anyone, but to improve the quality of services
rendered to T2D patients. With the student’s encouragement, all clinic staff agreed to support the
project.
Readiness for Change and Stakeholder Engagement
This clinic provided a supportive environment, and staff and providers were observed
working together as a team. Providers shared shift reports about daily events, which promoted
continuity of care. Initially, staff readiness to incorporate change was challenging. The owner, a
key stakeholder, is a medical doctor with excellent leadership skills but was not initially
convinced of the need for change. After the DNP student reviewed and discussed the ADA
(2018) evidence-based recommendations for patients who may have diabetic kidney disease and
the potential cost–benefit ratio, the owner became supportive of the project and asked the NPs,
manager, and MAs to commit to the quality improvement initiative. In addition to the physician,
the NPs, clinic manager, and MAs were stakeholders invested in their patients’ care and the wellbeing of the clinic. After the DNP student provided a full explanation of the project to all staff,
they became ready to institute a change in their clinical procedures and practices. Based on
findings from the patient satisfaction survey, patients also recognized a need for improvement in
quality of care and represented another major stakeholder.
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Project Identification
Purpose
The purpose of this quality improvement project was to implement the ADA 2018
evidence-based standards of care among patients with T2D related to annual urinary albumin
screening, eGFR, screening, and the use of ACE inhibitor or ARB therapy in non-pregnant
patients with T2D who demonstrated kidney disease.
Objectives and Anticipated Outcomes
1. Increase provider’s adherence to ADA (2018) guidelines for urine albumin screening
(ACR) and blood test for eGFR screening among patients with T2D.
Anticipated outcome: 80% of patients with T2D will receive a urine albumin screening
(ACR) and blood test for eGFR at least annually.
2. Increase provider initiation of ACE/ARB therapy for T2D patients who meet evidencebased criteria for an abnormal ACR or eGFR.
Anticipated outcome: Prescribed ACE or ARB therapy as indicated for patients with T2D
will increase from 25% to 80% by April 30, 2019.
3. Develop and distribute a patient educational pamphlet (Spanish and English) related to
the risks of kidney disease associated with T2D and the purpose of ACE inhibitor or
ARB therapy.
Anticipated outcome: Provider will approve the developed educational pamphlet, and
MAs will distribute it to patients with T2D when patients are placed in an exam room.
Summary and Strength of the Evidence
Healthy People 2020 has instituted objectives regarding diabetes outcomes, including an
objective to increase the proportion of persons with diabetes who receive an annual urinary
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microalbumin screening (U.S. Department of Health and Human Services [U.S. DHHS], 2019).
Additionally, Healthy People 2020 has set an objective to increase the proportion of people with
diagnosed diabetes and CKD who receive recommended treatment with ACE inhibitors or ARBs
(U.S. DHHS, 2019). These national objectives reflect the need for improvement in these
standards of care related to diabetes.
Members of the ADA Professional Practice Committee include physicians, advanced
practice registered nurses, pharmacists, and registered dieticians. These professionals have
developed a peer-reviewed process to establish goals, guidelines, and components of diabetes
care for the professional healthcare community. The practice recommendations are graded based
on level of evidence and are updated at least annually and published each year.
Recommendations are graded from highest to lowest as follows: A – evidence from random
controlled trials or meta-analysis is available and substantiates the recommendation(s); B –
evidence from strong cohort or case-control studies is available and supports the
recommendation(s); C – evidence from “poorly controlled” or uncontrolled studies is available;
and E – the recommendation is supported by “expert consensus or clinical experience” (ADA,
2018, p. S2). Please refer to Table 6 for project- related recommendations and grades of
evidence.
Method
Project Intervention
The providers and MAs were educated on the aim and scope of the project as well as the
steps to follow when patients with T2D visit the clinic. First, when a patient came in for an
appointment, the MA would check them in, identify whether the patient had T2D, and take a
medication history. Then, the MA would place a list of ACE inhibitors/ARBs in the record along
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Table 6
Standards of Medical Care in Diabetes
Standard

Grade of Evidence

At least once a year, assess urinary albumin (e.g., spot urinary albuminto-creatinine ratio) and estimated glomerular filtration rate in patients
with type 1 diabetes with duration of ≥ 5 years, in all patients with type
2 diabetes, and in all patients with comorbid hypertension.

B

In non-pregnant patients with diabetes and hypertension, either an ACE
inhibitor or an angiotensin receptor blocker is recommended for those
with modestly elevated urinary albumin-to-creatinine ratio (30– 299
mg/g creatinine) B and is strongly recommended for those with urinary
albumin-to-creatinine ratio ≥ 300 mg/g creatinine and/or estimated
glomerular filtration rate < 60 mL/min/1.73 m2.

A

An ACE inhibitor or an angiotensin receptor blocker is not
recommended for the primary prevention of diabetic kidney disease in
patients with diabetes who have normal blood pressure, normal urinary
albumin-to-creatinine ratio (< 30 mg/g creatinine), and normal
estimated glomerular filtration rate.

B

Note. Adapted from “American Diabetes Association standards of medical care in diabetes2018,” Diabetes Care, 41 S, S105–S106.
with a star sticker on the chart, which indicated to the provider that the patient was diabetic. The
providers, namely the medical doctor and NPs, would assess each patient’s medication list to see
if he/she was already taking an ACE or ARB. If no eGFR or urine ACR had been obtained for
baseline within the past 6 months, then urine was collected to check for ACR and blood was
drawn for eGFR to assess for albuminuria and proteinuria. If there was evidence of albuminuria
or proteinuria, an ACE inhibitor or ARB was to be ordered for the patient based on ADA
recommendations (2018). These tests could be obtained at the clinic, and results were available
within one to two hours.
For patients who met criteria to start an ACE inhibitor or ARB, the doctor, provider, or
DNP student educated patients on the benefits and side effects of these interventions. Most of the
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clinic’s MAs spoke Spanish, which afforded the DNP student and providers easy access to an
interpreter if a patient did not understand or speak English. Each patient was to be provided
brochures developed by the DNP student explaining the benefits and side effects of ACE
inhibitors and ARBs in either Spanish or English as appropriate; see Figure 1 for intervention
steps.
The provider was to place the patient on a renal dose of an ACE inhibitor/ARB if the
patient was not on a regimen already and met the ADA (2018) criteria. After a day, the MA was
to contact the patient to ensure that medication had been procured and taken as indicated. The
call was included as part of the clinic’s protocol of calling patients to make sure their medication
was filled and taken as prescribed. Each patient was asked to return to the clinic in 4–6 weeks
with his or her medication for re-evaluation.

Secretary

• Check the patient in and place star sticker on each T2D patient’s chart
• List of ACE/ARBs names placed in chart for MAs

Medical
Assistant

• Take medical and medication history
• Offer brochure in English/Spanish if patient has T2D

Provider

• Review chart for ACE/ARBs and labs; order labs as needed
• Order an ACE/ARB if criteria are met

Figure 1. Steps for intervention.
Organizational Barriers
Language was a primary barrier in this project. Eighty percent of the clinic population
was Hispanic, and most spoke little or no English; thus, they required a Spanish-speaking MA to
interpret during appointments and bridge this gap. The clinic’s charting system is 90% on paper,
which slowed the chart review process. Financial barriers could have presented obstacles for

IMPLEMENTATION OF ACE INHIBITOR REGIMEN

26

patients who were uninsured and paid cash for their visits. Another potential barrier involved the
subset of patients who do not earn a steady income and depend on stipends for survival. Lastly,
the cost of a new medication could be challenging for some patients to afford.
Facilitators
All clinic providers and staff verbalized their willingness to support and carry out all
project objectives by collecting a urine and blood sample to determine ACR and eGFR,
including implementing an ACE inhibitor or ARB regimen with T2D patients according to the
2018 Standards of Medical Care Guideline for Diabetes (ADA, 2018). Staff ensured that the
clinics stocked sufficient blood vacutainers, urine cups, needles, dipsticks, and in-house lab
equipment to conduct ACR and eGFR tests.
Ethical Considerations
All project information, including relevant diagnostic criteria, was submitted to the Ethics
Committee and Institutional Review Board (IRB) of the University of the Incarnate Word, and
this study was deemed non-regulated research. The project was reviewed and found not to meet
the federal regulatory requirements for human subjects’ research; hence, IRB approval was not
required. The owner of the clinic agreed to allow the DNP student to implement and evaluate
outcomes of this project and furnished a letter of support stating this; see Appendix B for a copy
of the letter.
Because many patients seen at the clinic were uninsured, the clinic owner decided to
allow free one-time lab (ACR and eGFR) work and 3 months of medication to interested lowincome T2D patients who could not afford to pay for lab work or procure their medication. Most
patients could afford these steps, and those who could not were given free samples of an ACE
inhibitor/ARB for 3 months.
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Results
The results of this quality improvement initiative are listed below according to the
corresponding project objective.
1. Increase provider’s adherence to ADA (2018) guidelines for urine albumin (ACR)
and blood test for eGFR screening among patients with T2D.
The anticipated outcome for this objective was set at 80%. During the implementation
period, 163 patients with T2D were screened for albuminuria and eGFR by obtaining urine for
ACR and eGFR from blood samples. Nineteen patients were not screened because they were
already on ACE/ARBs. Out of the remaining 144 patients, 132 tested positive for albuminuria
and 12 tested negative; thus, 100% of patients seen with T2D who were not already taking an
ACE/ARB were screened for albuminuria. In total, 91.6% exhibited symptoms indicative of
present or future CKD. The DNP student reviewed every T2D patient’s record weekly to
evaluate adherence to this objective and assess for any issues or barriers to implementation. This
objective was met and exceeded the goal. Table 7 outlines the weekly data collection used to
evaluate project outcomes.
2. Increase provider initiation of ACE/ARB therapy for T2D patients who meet
evidence- based criteria for an elevated ACR or eGFR.
The anticipated outcome for this objective was set at 80%. As stated previously, 19
patients were already receiving ACE/ARB therapy and did not meet inclusion criteria for this
objective; therefore, 144 patients could have received ACE/ARB therapy equals 144 patient. Of
those, 132 patients met the evidence-based criteria for albuminuria and were placed on an
ACE/ARB. Twelve patients were ineligible for ACE/ARB treatment as they did not have
albuminuria or eGFR of < 60. See Table 8 for related data.
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Table 9 presents a demographic overview of T2D patients seen at the clinic. About onequarter (27%) of patients reported having less than a high school education. Most patients were
of Hispanic descent followed by Asian descent. Patients age 66 and above had Medicare. Those
who were too young to have Medicare had private insurance; others paid for their visits in cash.
3. Develop and distribute patient educational pamphlet (Spanish and English) related to
the risks of kidney disease associated with T2D and the purpose of ACE inhibitor or
ARB therapy.
Two hundred brochures were developed in English and Spanish explaining the purpose
and benefits of ACE inhibitors/ARBs, and 163 brochures were given to all T2D patients seen;
see Appendix A for the sample brochure.
Discussion
The most notable success of this quality improvement project was the providers’
adherence to screening patients according to the ADA guideline: 163 T2D patients were
screened, and 132 received a prescription for an ACE inhibitor/ARB. Another success was to see
patients requesting to be screened based on the brochure provided during a prior visit. These
patients wanted to ensure they did not have albuminuria and that their eGFR was not < 60. Major
practice changes included the clinic automatically ordering labs for individuals with T2D who
had not received labs within the past 3 to 6 months and then placing those who met criteria on an
ACE inhibitor/ARB. The strength of this project was that the providers followed the guideline
recommendation of providing ACE inhibitors/ARBs to patients with T2D. A potential challenge
in this project was the language barrier, which the bilingual MAs helped to resolve. Another
potential obstacle concerned finances, which the owner of the clinic mitigated by offering onetime free labs to eligible patients experiencing financial difficulties.
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Table 7
Weekly Assessment Data Spreadsheet
Not on
ACE/ARB
(n = 144)
8

Placed on
ACE/ARB
(n = 132)
8

Not eligible

Wk. 1

Diabetic Patients Already on
(N = 163)
ACE/ARB
(n = 19)
8
0

Wk. 2

12

1

11

11

0

Wk. 3

13

1

12

12

0

Wk. 4

15

0

15

11

4

Wk. 5

13

3

10

9

1

Wk. 6

12

2

10

10

0

Wk. 7

11

0

11

9

2

Wk. 8

4

0

4

4

0

Wk. 9

14

1

13

10

3

Wk. 10

15

2

13

13

0

Wk. 11

19

2

17

16

1

Wk. 12

16

1

15

14

1

Wk. 13

4

1

3

3

0

Wk. 14

0

0

0

0

0

Wk. 15

5

3

2

2

0

Wk. 16

2

2

0

0

0

Week

(n = 12)
0

Table 8
Patient Data Analysis for 16 Weeks
Patient Characteristics
Eligible for and placed on ACE/ARB
Not eligible for ACE/ARB
Contraindication to ACE/ARB

Total (N = 144)

Percentage (%)

132
12
0

91.6
8.3
0
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Table 9
Demographics of T2D Patients Seen at the Clinic
Characteristics

Number of Patients
(N = 163)

Percentage (%)
(N = 163)

29
74
23
22
15

18
45
14
13
9

74
89

45
54

Ethnicity
Hispanic/Latino
Caucasian
Black/African American
Asian

95
25
11
32

58
15
7
20

Education
No education
Less than high school
High school/GED
Some college
College degree
Master’s degree

44
23
45
25
18
8

27
14
28
15
11
5

Insurance
Insured
Uninsured

72
91

44
56

25–35
36–45
46–55
56–65
66–75
Male
Female

Age

Gender
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The purpose of this quality improvement initiative was to implement ACE inhibitor or
ARB therapy in patients with T2D who met certain criteria; this intervention was intended to
enact an evidence-based guideline related to slowing the progression of CKD as a vital part of
chronic care of patients with T2D to promote prevention of complications (e.g., diabetic
nephropathy) (ADA, 2018).
Cooperation among the providers and other clinic staff contributed to the success of this
project. The staff followed the provided education and necessary steps (including in the absence
of the DNP student); they also expressed a good understanding of the process. The English and
Spanish brochure offered an overview of the advantages and side effects of ACE
inhibitors/ARBs, and patients understood the pamphlet well based on their feedback. Some
patients were initially reluctant to participate because they did not want to add more pills to their
regimen. However, after learning about the benefits of ACE inhibitors/ARBs, they agreed to take
part.
Limitations
Due to time constraints, this quality improvement project could not identify and track
every patient to verify if they had purchased or were taking the ACE/ARB medication as
prescribed. Even if the clinic staff were informed (e.g., via phone) that medication was procured
and that patients were taking it, a verbal report is not equivalent to providers seeing and counting
the pills remaining. Additionally, patients were not followed and seen at least 3 or 6 months after
to monitor for abnormal ACR or eGFR due to the time limits of this project.
Recommendations
To improve the scope of the project, the time frame could be extended to one year or
more and include a follow-up appointment. A longer intervention would permit more effective
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application of the evidence-based guideline to properly monitor patients’ kidney function by
screening T2D patients’ urine for albuminuria and blood sample for eGFR. Furthermore, a
tracking system should be put in place to track all patients and verify if medication was procured
and taken as prescribed. A follow-up plan for at least 3 to 6 months should be instituted to
monitor patients for side effects, answer their questions about the medication, and monitor
kidney function so patients can be referred to a nephrologist upon signs of progressive kidney
damage.
Implications for Practice
The American Association of Colleges of Nursing (AACN) has emphasized that a DNP
must recognize the scope of practice management along with theoretical and practical strategies
to balance productivity with quality of care. Doctorally prepared nurse practitioners are expected
to evaluate the impacts of practice policies and procedures on meeting the health requirements of
the patient populations they serve. Also, a DNP must be knowledgeable in quality improvement
strategies and in developing and sustaining change at the organizational and policy levels
(AACN, 2006). There is increased demand on primary care providers in the United States
because of changes in healthcare policy and an increase in a diverse and aging population; these
issues require active coordination and management of care for patients with chronic diseases
(Owens, 2018). The healthcare system is under pressure to provide cost-effective, high-quality
primary care due to rising patient expectations, shifting government regulations, and insurance
reimbursement (Owens, 2018). NPs, who comprise the most rapidly expanding segment of the
primary care workforce and play major roles on interprofessional healthcare teams, must
therefore assess patients appropriately. Responsibilities include ordering diagnostic tests and
making diagnoses; initiating, coordinating, and evaluating treatment plans; and prescribing
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medications (Owens, 2018).
Diabetic nephropathy is a serious complication of diabetes and is linked to significant
mortality and comorbidity. Nevertheless, there is a solid evidence base for therapies that can
prevent and slow the progression of CKD (Bilous, 2013). Regardless of clear screening and
adherence to recommended guidelines, diabetic nephropathy remains considerably
underdiagnosed (Kowalski, Krikorian, & Lerma, 2014). Current recommendations for early
detection of progression to CKD and yearly albumin-to-creatinine ratio and eGFR checks should
be uniformly implemented for all patients with T2D (Kowalski et al., 2014).
This quality improvement project focused on integrating an evidence-based practice
guideline into care being offered at the selected clinic. The project aligned with the DNP
essentials, which emphasize executive leadership, quality, service, process assessment, and
improvement to transform the healthcare field (Sherrod & Goda, 2016). The American
Association of Colleges of Nursing stresses that a DNP should possess the knowledge required to
effect quality patient outcomes (AACN, 2006, p. 9). The organizational and systems leadership
background that a DNP student obtains may improve patient and healthcare outcomes while
promoting patient safety and excellence in practice (AACN, 2006, p. 10). The DNP-prepared
leader should integrate nursing theory and scientific principles from the social sciences to
recognize and address poor outcomes or lack of adherence to evidence-based guidelines that
affect patient care. Doctorally prepared nurse practitioners should also be able to skillfully
educate and develop a systematic process that guides system change and conduct projects in
collaboration with other providers and healthcare staff to achieve high-quality patient outcomes.
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